The MAGenTA project consists into a collaborative work between four SMEs and two academic institutions. The aim is to develop new and innovative predictive experimental models in order to provide pharmaceutical companies and academic research with better tools that should facilitate the validation of gene candidates and discovery of new molecules. MAGenTA also includes two clinical studies which will enable validation of the effectiveness of two therapeutic molecules for urogenital diseases. The project has received the label of the Cancer Bio Santé cluster in Toulouse, France, in July 2012.
The project has started in January 2013 and is due to run for 5 years with a total project funding of €22.5 million.